

A

Attorney Docket No.: 5573.210-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

EXPRESS MAIL CERTIFICATE

Box Patent Application
Assistant Commissioner for Patents
Washington, DC 20231

Re: U.S. Patent Application for
"Compounds With Growth Hormone Releasing Properties"
Applicants: Peschke et al.

Sir:

Express Mail Label No. EL293688894US

Date of Deposit July 16, 1999

I hereby certify that the following attached paper(s) or fee

1. Filing Under 37 C.F.R. 1.53(b) (in duplicate)
2. Patent Application
3. Unexecuted Combined Declaration and Power of Attorney

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington, DC 20231.

Miriam Kelly

(Name of person mailing paper(s) or fee)

Miriam Kelly

(Signature of person mailing paper(s) or fee)

Mailing Address:

Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10017
(212) 867-0123



Attorney Docket No.: 5573.210-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

FILING UNDER 37 C.F.R. 1.53(b)

Box Patent Application
Assistant Commissioner for Patents
Washington, DC 20231

Express Mail Label No. EL293688894US

Date of Deposit July 16, 1999

Sir:

This is a request for filing a continuation-in-part application under 37 C.F.R. 1.53(b) of

Applicant(s): Peschke et al.

Title: Compounds With Growth Hormone Releasing Properties

130 pages of specification 3 sheets of Declaration and Power of Attorney

[x] The filing fee is calculated as follows:

Basic Fee:	\$760.00
Total Claims: $18 - 20 = 0 \times 18 =$	\$0
Independent Claims: $1 - 3 = 0 \times 78 =$	\$0
Total Fee:	\$760.00

Priority of Danish application nos. PA 1998 00857 and PA 1998 01440 filed on June 30, 1998 and November 9, 1998, respectively, is claimed under 35 U.S.C. 119. A certified copy thereof is submitted herewith.

Priority of U.S. provisional application nos. 60/091,786 and 60/108,369 filed on July 6, 1998 and November 13, 1998, respectively, is claimed under 35 U.S.C. 119.

The benefit of application no. 09/337,809 filed on June 21, 1999 in the U.S. is claimed under 35 U.S.C. 120.

Please amend the specification as follows: At page 1, after the title, insert

--CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of application no. 09/337,809 filed on June

Acet.

21, 1999 and claims priority under 35 U.S.C. 119 of United States Provisional application nos. 60/091,786 and 60/108,369 filed July 6, 1998 and November 13, 1998, respectively, and Danish application nos. PA 1998 00857 and PA 1998 01440 filed June 30, 1998 and November 9, 1998, respectively, the contents of which are fully incorporated herein by reference.--

Address all future communications to Steve T. Zelson, Esq., Novo Nordisk of North America, Inc., 405 Lexington Avenue, Suite 6400, New York, NY 10174-6401.

Please charge the required fee, estimated to be \$760, to Novo Nordisk of North America, Inc., Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: July 16, 1999

Carol E. Rozek

Carol E. Rozek, Reg. No. 36,993
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123